CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
December 06, 2016 01:05 ET
|
CELYAD S.A.
Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting Strong safety signals, including no cases of cytokine release syndrome, cell-related neurotoxicity,...
Interview vidéo Christian Homsy Directeur Général de Celyad
December 06, 2016 01:02 ET
|
CELYAD S.A.
COMMUNIQUÉ Paris, le 6 décembre 2016 Interview vidéo Christian Homsy Directeur Général Celyad Celyad (Euronext Bruxelles etParis, et NASDAQ : CYAD), leader dans la découverte et...
Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium
November 21, 2016 01:04 ET
|
CELYAD S.A.
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
Celyad announces third quarter 2016 business update
November 18, 2016 01:04 ET
|
CELYAD S.A.
First clinical trial of NKR-2 T-cells therapy completed with good safety outcome and unexpected signals of clinical activity at the low doses tested Strong cash management leading to a cash runway...
Celyad's NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016
November 07, 2016 01:28 ET
|
CELYAD S.A.
MONT-SAINT-GUIBERT, Belgium, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
CELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa
September 15, 2016 01:04 ET
|
CELYAD S.A.
MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
CELYAD S.A.: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
September 09, 2016 01:08 ET
|
CELYAD S.A.
Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
No safety issues or dose limiting toxicity reported.
The trial was a single...
Celyad Reports First Half 2016 Financial Results and Operational Progress
August 25, 2016 01:08 ET
|
CELYAD S.A.
MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of cell therapies, today announced its...
CELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial
July 14, 2016 01:04 ET
|
CELYAD S.A.
No safety issues or dose limiting toxicity reported in the first patient at the fourth dose level.
Next patient, 11th of the trial, has been infused.
The trial is a dose escalation study...
CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy
July 11, 2016 04:07 ET
|
CELYAD S.A.
Celyad grants an exclusive license to ONO for the development and commercialization of Celyad's unique allogeneic NKR-2 T-cell in Japan, Korea and Taiwan.
Celyad also grants to ONO an...